PHARMA
NBIX: Pharma higher highs!Neurocrine Biosciences, Inc.
Intraday - We look to Buy at 104.23 (stop at 98.97)
A sequence of intraday higher highs and lows has been posted. This is positive for sentiment and the uptrend has potential to return. A weaker opening is expected to challenge bullish resolve. Support is located at 104.00 and should stem dips to this area. Dip buying offers good risk/reward.
Our profit targets will be 120.54 and 128.00
Resistance: 121.00 / 136.00 / 140.00
Support: 104.00 / 80.00 / 55.00
Please be advised that the information presented on TradingView is provided to Vantage (‘Vantage Global Limited’, ‘we’) by a third-party provider (‘Signal Centre’) . Please be reminded that you are solely responsible for the trading decisions on your account. There is a very high degree of risk involved in trading. Any information and/or content is intended entirely for research, educational and informational purposes only and does not constitute investment or consultation advice or investment strategy. The information is not tailored to the investment needs of any specific person and therefore does not involve a consideration of any of the investment objectives, financial situation or needs of any viewer that may receive it. Kindly also note that past performance is not a reliable indicator of future results. Actual results may differ materially from those anticipated in forward-looking or past performance statements. We assume no liability as to the accuracy or completeness of any of the information and/or content provided herein and the Company cannot be held responsible for any omission, mistake nor for any loss or damage including without limitation to any loss of profit which may arise from reliance on any information supplied by Signal Centre.
ZYDUS LIFESCIENCES Parallel Channel Pattern Breakout*ZYDUS LIFESCIENCES*
Time Frame : Daily
Observation:
* Parallel Channel Pattern Breakout on Daily time frame
* 380 Swing High Break
* Mean (EMA) Diversion on Hourly time frame.
Resistance/Target: 401 420 452 486
Support: 350 329; Dynamic Support for EMA 200 on Hourly Time Frame.
APOLLOHOSP is forming triangle patternNSE:APOLLOHOSP Large cap Health care stock is forming triangle pattern with 4 months support line and 9 months resistance line with 4 rejections.
Previous support line was broken at 2022-04-29 and fallen 25%, hence this time enter only on strong breakout and follow strict SL.
Shorting can be attempted with triangle's support is broken strongly, and SL need to be followed strictly.
Key note : Always follow proper risk management to avoid losing capital from false breakouts as this is common.
Caution : This is a knowledge sharing analysis, not a call.
Profits are not made from following ideas, but by following Risk Management .
NIFTY PHARMA, REACHED ITS BOTTOM!!the dark black trend lines drawn are the actual positions where the nifty pharma should carry on, i have drawn a support line from the corona crash till date, which shows markets have bottomed. please do read the text mentioned in the graph, to understand my full analysis..
SOLARA ACTIVE PHARMA, AT A HUGE DISCOUNT!!i have marked the time of corona crash(2019), with a circle, this stock had not broken its support during a crash too, that means its a stable stock.
it has a good fundamentals, due to heavy corrections from past year, this stock had corrected a lot.
i have drawn a 5 wave pattern, and this stock will now stock its bull rally, as markets for large caps have corrected, and now its time for mid and small caps to get its bull run. (link provided below).
the stock has corrected till its IPO PRICE(when it touched its bottom).
this stock has a good future, invest for long term
Nifty Pharma- Support and Resistance ZoneNifty Pharma- Support and Resistance Zone
Consider buying Nifty Pharma stocks above resistance zone ( We can wait till 4 hours candle close above resistance)
Consider selling Nifty Pharma stocks below support zone ( We can wait till 4 hours candle close below support)
Mid term swing opportunity in CTI BioPharma (CTIC)Stock had decent drop right after earnings to the lowest channel support line.
Stock is heavily short : 20% of float is short
80% Institutional investors.
nice swing opportunity for a re-bounce to the upper "resistance" channel line.
NASDAQ:CTIC
ASND ( NASDAQ BIOTECH) rises on earnings and FDA submissionNASDAQ:ASND
as can be seen on the hourly chart ASND is in an uptrend
recent earnings were a good beat,
RSI is quite high and it is at one than one STD above
the multi-session VWAP.
ASND is on watch for a pullback to find an entry
as it has high upside.
CLVS signs of Life? Break outAfter following this since hit flat lined at .81 cent I saw clear cut signs of accumulation and break out. Right at the end of the option chain cycle. Which ended today. The fact that it jumped to above a $1 on this day shows to me that its serious about bouncing off the bottom. Otherwise it could have just stayed below $1 until after today. It jumping above a dollar today means someone lost money or that they dragged it so far down that even if it came up it didnt matter..... Now we have a full month in this option call to run. does it go parabolic? or does it re-accumulate from here to inch its way back up?
i marked two key areas in blue for when obvious change tot he price action can happen.
by iCantw84it
06.17.22
7/17/22 LLYEli Lilly and Company ( NYSE:LLY )
Sector: Health Technology (Pharmaceuticals: Major)
Market Capitalization: $315.073B
Current Price: $331.60
Breakout price: $334.70
Buy Zone (Top/Bottom Range): $314.00-$292.90
Price Target: $364.20-$367.50 (2nd)
Estimated Duration to Target: 112-120d (2nd)
Contract of Interest: $LLY 10/21/22 350c
Trade price as of publish date: $13.50/contract
Novavax - Wassup?Novavax NVAX is actually lining up pretty well... from about 240, it tanked to 40, and on Friday, it gained 11% to close the week at 57.15.
This caught my attention as it cleanly broke out of trendlines, breaking out also from a bearish divergence, on BOTH the weekly and daily chart.
IMHO, it appears to be in technical and fractal alignment.
Weekly chart bounced off a major support two weeks ago, and the last week continued the previous week's bullish end. On the daily chart, Friday's close was the highest daily close in about 5 weeks. with a strong candle closing draws obvious bullish attention.
Target 80, then 125.
Support at 53 and 50.
Moderna Progress on all VaccinesThe statistics are between $184 - $219(1 Year)
Its Financial Health is very strong.
Why not wait till Moderna makes greater progress and finds It
Resistance Again at $450
Moderna has many projects running.
So if we see progress in some of the projects in the next Years,
we will see a great price rise.
I believe it won't be difficult to reach its older resistance again, around $450.
Disclaimer:
Just my Idea! Find your Trading Ideas and learn and study more!
6/20/22 MRKMerck & Company, Inc. ( NYSE:MRK )
Sector: Health Technology (Pharmaceuticals: Major)
Market Capitalization: $213.987B
Current Price: $84.62
Breakout price: $91.40
Buy Zone (Top/Bottom Range): $83.60-$79.90
Price Target: $103.20-$105.80
Estimated Duration to Target: 672-696d
Contract of Interest: $MRK 1/19/24 85c
Trade price as of publish date: $10.17/contract
Sanofi - Pharming for profits?Sanofi
Short Term
We look to Buy at 95.00 (stop at 91.90)
The medium term bias remains bullish. Levels close to the 50% pullback level of 93.25 found buyers. Previous support located at 93.08. Further upside is expected and we look to set longs in early trade.
Our profit targets will be 104.35 and 110.00
Resistance: 95.16 / 98.22 / 104.35
Support: 93.25 / 93.08 / 92.78
Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features.
Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
SUNPHARMA (Trade the Trend) - BullishSUNPHARMA - Sun Pharmaceutical Industries Ltd. NSE:SUNPHARMA
After Q4 Results we saw a good sell-off in Sunpharma, yet the price hardly moved much
Shanghvi stated "Our India business continues to grow faster than the market, leading to an increase in market share. We continue to focus on expanding our global specialty business, growing all our businesses, and improving operational efficiencies," stated.
The company said its board has proposed a final dividend of Rs 3 per share for FY22.
One can plan a long position between 835 to 840 with a strict SL of Rs 825 for short term trading (01 to 02 weeks) and SL if the price moves below 825 (Daily candle close) for long term swing trading (greater than 2 weeks)
Short Term targets are up to - 886
Long Term Target is up to - 929
Risk Reward for this trade is very good
#Learn&earn #Wealth #Editor's Choice #trending #Weathmagnet candlestick analysis, candlestick stock pattern
Do Support by Liking and Commenting on our Post as it motivates us to post more such ideas
The chart is for study purposes only!!
Kindly consult your Financial Advisor before investing any money